Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000011440
- Lead Sponsor
- onprofit Organization Japan Clinical Cancer Research Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Not provided
(1) Synchronous multiple maligmancy or metachronous multiple malignancy within 5 years disease free interval (2) Symptomatic brain metastases (3) Severe infectious disease (4) Comorbidity or history of interstitial lung disease or pulmonary fibrosis (5) Comorbidity or history of severe heart disease (6) Sensory alteration or paresthesia interfering with function (7) Large quantity of pleural, abdominal or cardiac effusion (8) Severe comobidity (renal failure, liver failure, hypertensio, etc) (9) Prio radiotherapy for primary and metastatic tumor (10) Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (11) Any other cases who are regarded as inadequate for study enrillment by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-Month Progression Free Survival Rate
- Secondary Outcome Measures
Name Time Method response rate disease control rate overall survival progression free survival time to treatment failure safety